|
|
| Stratégie - Organisation > Etude de marché sectorielle |
| The Blockbuster Drugs Outlook: Optimum management strategies throughout the product lifecycle |
|
|
|
|
€ 955,00 |
Editeur
: |
Business Insight |
Langue
: |
Anglais |
Date de publication : |
Mai 2001 |
Taille du document : |
258 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Sainsbury's Blue Parrot Café case study: marketing nutritious kids' food to families
14 pages | Mars 2004 |
IntroductionThis report on Sainsbury's Blue Parrot Café forms part of Datamonitor's case studies series, which explores business practices across a variety of disciplines and business sectors.
Each |
236,00 €
|
| |
| |
Market Research in France
18 pages | Novembre 2004 |
Datamonitor's Market Research in France industry profile is an essential resource for top-level data and analysis covering the market research industry.
It includes data on market size and segmenta |
160,00 €
|
| |
| |
Market Research in Italy
19 pages | Novembre 2004 |
Datamonitor's Market Research in Italy industry profile is an essential resource for top-level data and analysis covering the market research industry.
It includes data on market size and segmentat |
160,00 €
|
| |
| |
Market Research in Belgium
19 pages | Novembre 2004 |
Datamonitor's Market Research in Belgium industry profile is an essential resource for top-level data and analysis covering the market research industry.
It includes data on market size and segment |
160,00 €
|
| |
| |
Adding Cool To Your Brand in 2005
73 pages | Janvier 2005 |
IntroductionConsumers are becoming more image conscious and are purchasing products that support their lifestyle to provide an aspired image.
A common marketing myth claims that coolness is only im |
4 556,00 €
|
| |
| |
Enterprise Architecture
252 pages | Février 2004 |
Butler Group believes that now is the time for organisations to start considering and deploying Enterprise Architecture based around a balanced business process and information view of operations.
|
1 195,00 €
|
| |
| |
Market Research in China
18 pages | Novembre 2004 |
Datamonitor's Market Research in China industry profile is an essential resource for top-level data and analysis covering the market research industry.
It includes data on market size and segmentat |
160,00 €
|
| |
| |
Achieving Market Dominance Through Reformulation: A Strategic Insight
218 pages | Août 2001 |
More than $165bn in ethical revenues may be cannibalised as a consequence of patent expiry from 31 leading drug patent expirations between 2000 and 2005.
In view of this, pharmaceutical reformulati |
955,00 €
|
| |
| |
IT Performance Optimisation
288 pages | Novembre 2004 |
The report focuses on what happens to software applications after they are deployed in live production use – how to extract maximum performance, how to troubleshoot when problems occur.
The report |
1 195,00 €
|
| |
| |
Tapping the Malaysian Wealth Market
46 pages | Février 2005 |
IntroductionThis report looks at the size and composition of the wealth market in Malaysia, analyzing the opportunities that exist for regional and local players and providing the best strategies for |
2 236,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| The Blockbuster Drugs Outlook: Optimum management strategies throughout the product lifecycle |
|
|
Cost containment pressures have increased the need for pharmaceutical companies
to launch innovative, new drugs with sales potentials in excess of $1bn.
In addition to this, companies must ensure maximum profit from their blockbusters
even after patent expiry.
The Blockbuster Drug Outlook: Optimum management strategies throughout
the product life-cycle, a new management report identifies current and potential
areas for blockbuster development, matching R&D activities against unmet need.
It further analyses how companies can manage blockbuster drugs within their
portfolios over the long-term and how their non-blockbusting competitors can
best survive.
The report examines both generic issues and trends in their route to commercial
success, and the market dynamics of individual drugs.
By drawing on detailed profiles of current blockbusters, best practice in product
launch and sales protection in the face of patent expiry can be identified.
In addition, analysis of current blockbuster drugs provides insight into future
opportunities for such high selling products.
|
|
Chapter 1: Introduction to the blockbuster market
Chapter 2: Managing blockbusters 36
Chapter 3: The current blockbuster market
Chapter 4: Profiles of current blockbuster drugs
Chapter 5: Blockbusters of the future
|
|
|
PPLSEN
|
|
|
|
|
